Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Am Soc Clin Oncol Educ Book. 2019 May 17;39:500–518. doi: 10.1200/EDBK_239067

FIGURE 1. Newly Diagnosed Patients With MM: Approach to Treatment.

FIGURE 1.

Abbreviations: ADL, activities of daily living; ALT, alanine aminotransferase; ASCT, autologous stem cell transplantation; AST, aspartate aminotransferase; CCI, Charlson comorbidity index; Dara, daratumumab; DLCO, diffusion capacity of carbon monoxide; FEV1, forced expiratory volume in 1 second; IADL, instrumental ADLs; IMWG, International Myeloma Working Group; LVEF, left ventricular ejection fraction; MEL, melphalan (with dosages in mg/m2); MM, multiple myeloma; Rd, lenalidomide and dexamethasone; Rd-R, lenalidomide and dexamethasone followed by lenalidomide maintenance; rMCI, revised myeloma comorbidity index; ULN, upper limit of normal; VCd, bortezomib, cyclophosphamide, dexamethasone; VMP, bortezomib, melphalan, and prednisone; VRd/vrd, bortezomib, lenalidomide, and dexamethasone. (*) If daratumumab-based combinations or VRd are unavailable. (°) The lowercase letter indicates a reduced dose.